DRW3 logo

Drägerwerk AG & Co. KGaA Stock Price

XTRA:DRW3 Community·€1.1b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author

DRW3 Share Price Performance

€65.70
17.40 (36.02%)
31.6% undervalued intrinsic discount
€96.00
Fair Value
€65.70
17.40 (36.02%)
31.6% undervalued intrinsic discount
€96.00
Fair Value
Price €65.70
AnalystHighTarget €96.00
AnalystConsensusTarget €76.60
AnalystLowTarget €63.00

DRW3 Community Narratives

AnalystHighTarget·
Fair Value €96 32.0% undervalued intrinsic discount

Aging Populations And Digital Health Will Transform Global Demand

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystConsensusTarget·
Fair Value €76.6 14.8% undervalued intrinsic discount

Global Medical Demand Will Unlock Future Markets

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AnalystLowTarget·
Fair Value €63 3.7% overvalued intrinsic discount

Regulatory Burdens And Procurement Consolidation Will Weaken Operating Margins

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Recent DRW3 News & Updates

Drägerwerk AG & Co. KGaA Key Details

€3.4b

Revenue

€1.9b

Cost of Revenue

€1.5b

Gross Profit

€1.4b

Other Expenses

€99.9m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 29, 2025
Earnings per share (EPS)
5.32
Gross Margin
44.86%
Net Profit Margin
2.97%
Debt/Equity Ratio
22.3%

Drägerwerk AG & Co. KGaA Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Undervalued with excellent balance sheet and pays a dividend.

2 Risks
3 Rewards

About DRW3

Founded
1889
Employees
16609
CEO
Stefan Drager
WebsiteView website
www.draeger.com

Drägerwerk AG & Co. KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, devices, and services for the medical division, including emergency medicine, perioperative care, intensive care, and perinatal medicine. The company also develops, produces, and markets products, system solutions, and services for personal protection, gas measurement technology, and comprehensive risk management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. Its products include patient monitoring systems; anaesthesia machines; medical ventilators and lung monitoring; neonatal incubators and thermoregulation; phototherapy lights and bilirubinometers; surgical and examination lights; medical pendants and infrastructure design; medical gas pipeline system in hospitals; and hospital consumables and accessories, as well as hospital planning and design services. In addition, the company offers alcohol and drug testing; fixed gas detectors; hazmat suits; portable gas detection; head protection; rescue and escape; respiratory protection; safety-training systems; thermal imaging cameras; and workshop solution and breathing gas supply. Further, it provides various training and services. The company was founded in 1889 and is headquartered in Lübeck, Germany. Drägerwerk AG & Co. KGaA operates as a subsidiary of Stefan DrÄGer Gmbh.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

German Market Performance

  • 7 Days: -1.0%
  • 3 Months: -1.6%
  • 1 Year: 12.4%
  • Year to Date: 12.1%
Over the last 7 days, the market has dropped 1.0%, driven by losses in the Consumer Discretionary and Industrials sectors of 4.0% and 1.8%, respectively. As for the longer term, the market has actually risen by 12% in the last year. As for the next few years, earnings are expected to grow by 17% per annum. Market details ›